

NCT02339974 Raw comparison:

Summary:
CHIA has 24 criteria while your personal folder has 26 criteria
Total found criteria: 24/24
Total not Found: 0/24
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Patients must be at least 21 years old             │ Patients must be at least 21 years old             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The patient must have severe symptomatic (ACC/AHA  │ The patient must have severe symptomatic (ACC/AHA  │
│ Stage D symptoms) tricuspid regurgitation (TR) as  │ Stage D symptoms) tricuspid regurgitation (TR) as  │
│ assessed by 2D echocardiogram with evidence of     │ assessed by 2D echocardiogram with evidence of     │
│ peripheral and central venous congestion           │ peripheral and central venous congestion           │
│ (specifically lower extremity edema and abdominal  │ (specifically lower extremity edema and abdominal  │
│ ascites requiring diuretics )                      │ ascites requiring diuretics )                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The patient must be evaluated by a "heart team" of │ The patient must be evaluated by a "heart team" of │
│ physicians including an interventional             │ physicians including an interventional             │
│ cardiologist cardiothoracic surgeon heart failure  │ cardiologist cardiothoracic surgeon heart failure  │
│ specialist and imaging specialist and presented    │ specialist and imaging specialist and presented    │
│ for review at a local multi-disciplinary           │ for review at a local multi-disciplinary           │
│ conference By consensus the heart team must agree  │ conference By consensus the heart team must agree  │
│ (and verify in the case review process) that valve │ (and verify in the case review process) that valve │
│ implantation will likely benefit the patient       │ implantation will likely benefit the patient       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The heart team must agree that medical factors     │ The heart team must agree that medical factors     │
│ preclude operation based on a conclusion that the  │ preclude operation based on a conclusion that the  │
│ probability of death or serious irreversible       │ probability of death or serious irreversible       │
│ morbidity exceeds the probability of meaningful    │ morbidity exceeds the probability of meaningful    │
│ improvement Also other factors which may increase  │ improvement Also other factors which may increase  │
│ the patients perceived surgical risk for inclusion │ the patients perceived surgical risk for inclusion │
│ in the trial will be clearly delineated if they    │ in the trial will be clearly delineated if they    │
│ are present These include but are not limited to   │ are present These include but are not limited to   │
│ the following as defined by VARC 2 Frailty Hostile │ the following as defined by VARC 2 Frailty Hostile │
│ chest porcelain aorta IMA or other critical        │ chest porcelain aorta IMA or other critical        │
│ conduit crossing the midline or adherent to the    │ conduit crossing the midline or adherent to the    │
│ posterior table of sternum severe right            │ posterior table of sternum severe right            │
│ ventricular (RV) dysfunction The surgeons'         │ ventricular (RV) dysfunction The surgeons'         │
│ consultation notes shall specify the medical or    │ consultation notes shall specify the medical or    │
│ anatomic factors leading to that conclusion At     │ anatomic factors leading to that conclusion At     │
│ least one of the cardiac surgeon assessors must    │ least one of the cardiac surgeon assessors must    │
│ have interviewed and examined the patient          │ have interviewed and examined the patient          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The study patient provides informed consent and    │ The study patient provides informed consent and    │
│ agrees to comply with all required post-procedure  │ agrees to comply with all required post-procedure  │
│ follow-up visits including annual visits up to 5   │ follow-up visits including annual visits up to 5   │
│ years                                              │ years                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Heart Team assessment of operability (the heart    │ Heart Team assessment of operability (the heart    │
│ team considers the patient to be a good surgical   │ team considers the patient to be a good surgical   │
│ candidate)                                         │ candidate)                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of an acute myocardial infarction = 1     │ Evidence of an acute myocardial infarction ≤ 1     │
│ month (30 days) before the intended treatment      │ month (30 days) before the intended treatment      │
│ [defined as Q wave MI or non-Q wave MI with total  │ \[defined as Q wave MI or non-Q wave MI with total │
│ CK elevation of CK-MB = twice normal in the        │ CK elevation of CK-MB ≥ twice normal in the        │
│ presence of MB elevation and/or troponin level     │ presence of MB elevation and/or troponin level     │
│ elevation (WHO definition)]                        │ elevation (WHO definition)\]                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Untreated severe left sided valvular heart disease │ Untreated severe left sided valvular heart disease │
│ including mitral regurgitation or stenosis and     │ including mitral regurgitation or stenosis and     │
│ aortic regurgitation or stenosis                   │ aortic regurgitation or stenosis                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Mean pulmonary artery pressures =40mmHG and PVR >4 │ Mean pulmonary artery pressures ≥40mmHG and PVR    │
│ woods units as assessed by right heart             │ \>4 woods units as assessed by right heart         │
│ catheterization                                    │ catheterization                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any therapeutic invasive cardiac procedure         │ Any therapeutic invasive cardiac procedure         │
│ resulting in a permanent implant that is performed │ resulting in a permanent implant that is performed │
│ within 30 days of the index procedure Examples of  │ within 30 days of the index procedure Examples of  │
│ permanent implant would include any new heart      │ permanent implant would include any new heart      │
│ valve Implantation of a permanent pacemaker is     │ valve Implantation of a permanent pacemaker is     │
│ excluded                                           │ excluded                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with planned concomitant surgical or      │ Patients with planned concomitant surgical or      │
│ transcatheter ablation for Atrial Fibrillation     │ transcatheter ablation for Atrial Fibrillation     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Leukopenia (WBC < 3000 cell/mL) acute anemia (Hgb  │ Leukopenia (WBC \< 3000 cell/mL) acute anemia (Hgb │
│ < 9 g/dL) Thrombocytopenia (Plt < 50 000 cell/mL)  │ \< 9 g/dL) Thrombocytopenia (Plt \< 50 000         │
│                                                    │ cell/mL)                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemodynamic or respiratory instability requiring   │ Hemodynamic or respiratory instability requiring   │
│ inotropic support mechanical ventilation or        │ inotropic support mechanical ventilation or        │
│ mechanical heart assistance within 30 days of      │ mechanical heart assistance within 30 days of      │
│ screening evaluation                               │ screening evaluation                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Need for emergency surgery for any reason          │ Need for emergency surgery for any reason          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Left ventricular ejection fraction <40%            │ Left ventricular ejection fraction \<40%           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Echocardiographic evidence of intracardiac mass    │ Echocardiographic evidence of intracardiac mass    │
│ thrombus or vegetation                             │ thrombus or vegetation                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active upper GI bleeding within 3 months (90 days) │ Active upper GI bleeding within 3 months (90 days) │
│ prior to procedure                                 │ prior to procedure                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A known contraindication or hypersensitivity to    │ A known contraindication or hypersensitivity to    │
│ all anticoagulation regimens or inability to be    │ all anticoagulation regimens or inability to be    │
│ anticoagulated for the study procedure             │ anticoagulated for the study procedure             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Recent CVA clinically confirmed (by neurologist)   │ Recent CVA clinically confirmed (by neurologist)   │
│ or neuroimaging confirmed stroke or transient      │ or neuroimaging confirmed stroke or transient      │
│ ischemic attack (TIA) within 6 months (180 days)   │ ischemic attack (TIA) within 6 months (180 days)   │
│ of the procedure                                   │ of the procedure                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Estimated life expectancy < 1 year from conditions │ Estimated life expectancy \< 1 year from           │
│ other than TR                                      │ conditions other than TR                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Expectation that patient will not improve despite  │ Expectation that patient will not improve despite  │
│ treatment of tricuspid regurgitation               │ treatment of tricuspid regurgitation               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Currently participating in another investigational │ Currently participating in another investigational │
│ cardiac device study or any other clinical trial   │ cardiac device study or any other clinical trial   │
│ including drugs or biologics Note Trials requiring │ including drugs or biologics Note Trials requiring │
│ extended follow-up for products that were          │ extended follow-up for products that were          │
│ investigational but have since become commercially │ investigational but have since become commercially │
│ available are not considered investigational       │ available are not considered investigational       │
│ trials                                             │ trials                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active bacterial endocarditis within 6 months (180 │ Active bacterial endocarditis within 6 months (180 │
│ days) of procedure                                 │ days) of procedure                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with signs or symptoms of SVC syndrome or │ Patients with signs or symptoms of SVC syndrome or │
│ hepatic cirrhosis not felt due to passive          │ hepatic cirrhosis not felt due to passive          │
│ congestion from TR                                 │ congestion from TR                                 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Must have minimum age of 22 Years                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ 20 Subject unable to personally provide informed consent 21 FEV1\<30% of predicted 22 Model for End │
│ State Liver Disease (MELD) score ≥21 (calculated per reference study                                │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛